Production of functional plasmacytoid dendritic cells – targeted chimeric antigen receptor T cells from patients with immune-mediated inflammatory diseases.

Production of functional plasmacytoid dendritic cells - targeted chimeric antigen receptor T cells from patients with immune-mediated inflammatory diseases After 15 days of culture, CAR123 expression was stable in both cases (Figure 1a) and CAR123 maintained a good proliferation rate: 244.3 ± 201.4% for patients ( I n i = 23) and 571.6 ± 294.5% for HD ( I n i = 5) ( I P i = 0.0052) (Figure 1b). Https://doi.org/10.1093/bjd/ljad105 Dear Editor, Mainly developed in the field of oncology, chimeric antigen receptor T-cell (CAR-T cell) therapy has been extended more recently to other areas such as infectious diseases, cardiac fibrosis or autoimmune diseases (AIDs).[1] Patients with refractory systemic lupus erythematosus (SLE) treated with CD19-targeted CAR-T cells demonstrated an improvement of clinical symptoms and normalization of laboratory parameters including seroconversion of anti-double-stranded DNA antibodies along with a deep depletion of B cells.[2] Increasing evidence suggests that plasmacytoid dendritic cells (pDCs) are involved in the development of different pDC-driven AIDs and immune-mediated inflammatory diseases (IMIDs), especially through the overproduction of proinflammatory cytokines such as type 1 interferons.[3] It is thus conceivable that elimination of pDCs might be beneficial to improve AID and IMID evolution as was recently demonstrated in a phase II trial involving patients with SLE treated with an antibody-binding of blood dendritic cell antigen 2 (BDCA2).[4] To the best of our knowledge, no CD123-targeted CAR-T cells (CAR123) have yet been developed for AID and IMID treatment. [Extracted from the article]